Gioia Colafigli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients	EXPERT REVIEW OF HEMATOLOGY	2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents	CURRENT CANCER DRUG TARGETS	2022
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation	JOURNAL OF CLINICAL MEDICINE	2022
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols	ACTA ONCOLOGICA	2021
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience	LEUKEMIA & LYMPHOMA	2021
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?	BLOOD REVIEWS	2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up	LEUKEMIA & LYMPHOMA	2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2021
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up	LEUKEMIA & LYMPHOMA	2021
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab	ANNALS OF HEMATOLOGY	2021
Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A ``Campus CML{''} Study	BLOOD	2021
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia	BLOOD	2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2021
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2021
Measuring prognosis in chronic myeloid leukemia: what's new?	EXPERT REVIEW OF HEMATOLOGY	2021
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols	ACTA ONCOLOGICA	2021
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study	ACTA ONCOLOGICA	2021
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience	ANNALS OF HEMATOLOGY	2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	EXPERT REVIEW OF HEMATOLOGY	2020